These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19595310)

  • 1. Oxidative stress and lymphocyte persistence: implications in immunotherapy.
    Mehrotra S; Mougiakakos D; Johansson CC; Voelkel-Johnson C; Kiessling R
    Adv Cancer Res; 2009; 102():197-227. PubMed ID: 19595310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting costimulatory pathways for tumor immunotherapy.
    Ward RC; Kaufman HL
    Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
    Whiteside TL
    Semin Cancer Biol; 2006 Feb; 16(1):3-15. PubMed ID: 16153857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the immune response to monitor tumor immunotherapy.
    Wang Q; Ornstein M; Kaufman HL
    Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From cancer immunosurveillance to cancer immunotherapy.
    Stagg J; Johnstone RW; Smyth MJ
    Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies to improve tumor immunotherapy.
    Begley J; Ribas A
    Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytotoxic T lymphocytes in cancer and autoimmunity].
    Prado-García H; Avila-Moreno F; López-González JS
    Rev Invest Clin; 2004; 56(5):629-39. PubMed ID: 15776868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging strategies in regulatory T-cell immunotherapies.
    Gajewski TF; Chesney J; Curriel TJ
    Clin Adv Hematol Oncol; 2009 Jan; 7(1):1-10; quiz 11-2. PubMed ID: 19288606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-traditional immunogens and their application to immunotherapy.
    Chatterjee M; Tainsky MA
    Curr Opin Mol Ther; 2008 Feb; 10(1):62-7. PubMed ID: 18228183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
    Berry LJ; Moeller M; Darcy PK
    Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.
    de Souza AP; Bonorino C
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune responses inhibit the antitumor activities mediated by Salmonella enterica serovar choleraesuis.
    Lee CH; Wu CL; Chen SH; Shiau AL
    J Immunother; 2009 May; 32(4):376-88. PubMed ID: 19342967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
    Talmadge JE
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
    Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
    Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.